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Jean Dallongeville and Aline Meirhaeghe suggest that caution should be exercised in interpreting our study because the results might not necessarily indicate a role for hypertriglyceridaemia itself, especially since triglyceride metabolism is modulated by factors such as diabetes, obesity, and smoking. It was due to such considerations that the title and conclusions of our report related to "triglyceride-mediated pathways" rather than to hypertriglyceridaemia. (Our study showed that the APOA5 -1131T>C genotype is not materially correlated to the prevalence of diabetes, obesity, and smoking.) Di Zeng and colleagues describe potential limitations of genetic association studies, including the possibility of confounding by other genetic loci, unrecognised geneenvironmental interactions, and developmental compensation. We anticipated such potential limitations in our paper, stating, for example, that future studies should aim to include several (unlinked) genetic variants as deconfounding tools, because if they produce congruent predictions to those in our report, the scope for such confounding would be reduced.
As stated in our report, our study's main limitation was lack of access to individual participant data for the genetic component, which is now being addressed in a further collaborative investigation.
We declare that we have no confl icts of interest. WHO/PQP does indeed do a "stringent quality check" of any medicinal product submitted to it for assessment. However, the check is not "imposed" but part of a process that manufacturers undergo voluntarily and at no cost to themselves.
*Nadeem
Analysis of sampling and testing results for antimalarials indicates that prequalifi cation by WHO is a strong indicator of a medicine's quality. In a study funded by the European Union (as yet unpublished), 935 samples were collected in 2008 in Cameroon, Ethiopia, Ghana, Kenya, Nigeria, and Tanzania. Quality-control laboratories tested about 30% of the samples. Only three (3·6%) of the 83 samples of WHO-pre qualifi ed antimalarials deviated from prespecifi ed quality criteria, compared with 73 (39·7%) of the 184 samples of non-WHOprequalifi ed antimalarials.
The study also compared the results of minilabs used to screen medicines in the fi eld with those of qualitycontrol laboratories. The qualitycontrol laboratories identifi ed a greater number of poor-quality antimalarials than did the minilabs. WHO/PQP has so far prequalifi ed 14 quality-control laboratories, and a further 30 (16 in sub-Saharan Africa) are working towards prequalifi cation.
Anderson mentions the eff orts of Deutsche Gesellschaft für Technische Zusammenarbeit (GTZ) to help African manufacturers identify the improve ments necessary to reach international standards, but not similar eff orts undertaken by WHO/ PQP. In fact, WHO/PQP works with many national regulatory authorities, quality-control laboratories, and manufacturers, in numerous developing countries, to help them acquire the skills needed for ensuring medicines quality.
Local manufacturing in Africa re mains a diffi cult issue since compliance with international standards within Africa varies signifi cantly. But WHO/PQP targets resources and eff orts to boost both the quality of that production, and the capacity to ensure that it is monitored and maintained. We believe that our eff orts, combined with those of many other parties, can contribute to better medicines for Africa. Our aspiration, however, is that any local pharmaceutical production, independent of its location, meets quality standards.
We declare that we have no confl icts of interest. 
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